Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab And Randomized Phase 2B Study Of Nogapendekin Alfa Inbakicept, Bevacizumab, And Tumor Treatment Fields With Or Without PD-L1 T-HaNK In Participants With Recurrent Or Progressive Glioblastoma

This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a safety lead-in followed by a randomized Phase 2 comparison of a de-intensified experimental chemoradiation approach versus standard-of-care chemoradiation.

开始日期2026-07-22

申办/合作机构

ImmunityBio, Inc.

NCT07578558

/ Not yet recruiting临床2期

Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia

This is a Phase 2, randomized, open-label study evaluating the safety and efficacy of nogapendekin alfa inbakicept (NAI, ANKTIVA®) in combination with standard of care versus standard of care alone in critically ill adults with sepsis and persistent lymphopenia. The study aims to determine whether NAI can improve 28-day mortality by addressing the immunosuppressive phase of sepsis characterized by persistent lymphopenia (absolute lymphocyte count <1,000 cells/µL). Participants will be randomized 1:1 to receive either NAI 1.2 mg subcutaneous injection on Days 3 (or earlier if ALC <700 cells/µL), Day 14, and potentially Day 21 if ALC remains <1,000 cells/µL, plus standard of care, or standard of care alone. The study will enroll approximately 50 participants (25 per arm) with persistent lymphopenia.

开始日期2026-07-06

申办/合作机构

ImmunityBio, Inc.

NCT07355205

/ Not yet recruiting临床2期IIT

A Phase II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

This is an open-label, single center, one cohort, non-randomized, phase II study. The aim of the study is to evaluate the efficacy and safety of the combination of nivolumab and ipilimumab with nogapendekin alfa inbakicept in patients with stage IV or recurrent non-small cell lung cancer (NSCLC). It is hypothesized that the study treatment will be safe and well tolerated and will improve progression-free survival when compared to a historical study which treated advanced NSCLC patients with nivolumab plus ipilimumab. Patients will be treated in cycles lasting 6 weeks with two to three different chemotherapy drugs to up to 24 months.

开始日期2026-06-30

申办/合作机构

Washington University School of Medicine

[+2]

100 项与诺格白介素α-因奇西普相关的临床结果

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的转化医学

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的专利（医药）

登录后查看更多信息

379

项与诺格白介素α-因奇西普相关的文献（医药）

2026-12-31·Emerging Microbes & Infections

Neuraminidase-inhibiting antibodies boosted by H1N1pdm infection cross-react differently with H5N1 of clades 2.3.4.4b and 2.3.2.1a

Article

作者: Aziz, Dinah Binte ; Tan, Yee-Joo ; Chan, Yee Teng ; Liew, Kong Yen ; Tambyah, Paul ; Tan, Chee Wah

Antibodies against neuraminidase (NA) are an independent correlate of protection and the antigenic relatedness between H1N1pdm and H5N1 NAs suggests that seasonal influenza infection may provide cross-reactive immunity. In this study, recent H1N1pdm infection elicited modest NA-inhibiting (NAI) antibody responses against contemporary A/Victoria/4897/2022 (H1N1pdm) but strong responses against older A/California/7/2009 (H1N1pdm). Convalescent sera exhibited significantly higher cross-reactive NAI against clade 2.3.4.4b H5N1 (A/Texas/37/2024) than non-flu A patients, whereas H3N2 infection did not elicit such cross-reactivity. NAI titres were comparable between N1-California and N1-Texas but lower against N1-Victoria, indicating greater antigenic similarity between N1-California and N1-Texas. This was supported by stronger inhibition of N1-Texas by N1-California sheep antiserum compared with N1-Victoria sheep antiserum. Surprisingly, H1N1pdm-infected patients exhibited very low NAI against clade 2.3.2.1a H5N1 (N1-Bangladesh; GMT of 171 vs GMT 1159 for N1-Texas). Mouse antisera demonstrated reduced reciprocal inhibition between N1-Texas and N1-Bangladesh, consistent with their antigenic divergence. When four residues in N1-Bangladesh were substituted with their corresponding residues in N1-Texas, N1-Bangladesh antiserum showed reduced NAI, while N1-Texas antisera showed increased inhibition compared with wild-type N1-Bangladesh. This suggests that these amino acid differences are partially responsible for their antigenic divergence. Importantly, longitudinal analysis revealed that boosted cross-reactive NAI responses waned by day 90 post-infection, highlighting their limited durability. Together, these findings demonstrate that seasonal H1N1pdm infection can transiently boost cross-reactive NAI antibodies against clade 2.3.4.4b H5N1, but antigenic divergence in clade 2.3.2.1a limits cross-reactivity. As such, the impact of pre-existing antibody during an H5N1 outbreak is dependent on the infecting clade.

2026-06-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Advances in intravesical therapy for non-muscle-invasive bladder cancer

Review

作者: Tang, Yanfeng ; Zeng, Hao ; Zhu, Qiyu ; Xu, Chenhao ; Chen, Junru ; Liu, Haoyang ; Wang, Ling

Non-muscle-invasive bladder cancer (NMIBC) accounts for roughly 75% of newly diagnosed bladder cancer and associates with high risk of recurrence and progression. Intravesical therapy remains the cornerstone of NMIBC management following transurethral resection of bladder tumor (TURBT). For low-risk NMIBC, immediate single instillation of chemotherapy after TURBT effectively reduces recurrence. Intermediate-risk patients could benefit from either intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) instillation, with emerging therapies such as UGN-102 chemoablation showing promise. For high/very high-risk NMIBC, full-dose, 3-year BCG instillation remains the standard of care, However, global BCG shortages and treatment failures have prompted the need for alternative strategies. Optimization of BCG regimens, such as two induction courses, may preserve efficacy while improving feasibility. Moreover, alternative agents such as sequential gemcitabine and docetaxel instillation have demonstrated favorable outcomes in both BCG-naïve and BCG-unresponsive patients. For those with BCG failure, a number of novel therapies are under active investigation. Gene therapy (nadofaragene firadenovec), oncolytic viral therapy (CG0070), interleukin-15 superagonist (Nogapendekin alfa-inbakicept), and innovative drug delivery systems (TAR-200) have shown encouraging clinical potential in this population. This review provides an overview of current intravesical treatment strategies for NMIBC across different risk groups and highlights promising new approaches aimed at overcoming the limitations of BCG therapy.

2026-05-01·Biomaterials advances

A novel ROS switcher potentiates the type-I photodynamic effect of sodium zinc chlorophyllin against Pseudomonas aeruginosa in diabetic wounds

Article

作者: Yuan, Cai ; Wang, Guodong ; Chen, Hongjie ; Huang, Mingdong ; Wu, Lusheng

Skin wound infections present a serious threat to human health, with bacterial infections in diabetic wounds being particularly challenging due to impaired healing. Gram-negative bacteria are common pathogens in diabetic wound infections and often exhibit high resistance to conventional treatments, necessitating prolonged and costly therapies. Photodynamic antibacterial therapy (PACT) is regarded as a non-invasive and effective approach, with minimal risk of inducing resistance. Sodium zinc chlorophyllin (ZnChl), a water-soluble metalloporphyrin photosensitizer, offers multiple advantages such as low cost, high safety, and the ability to promote wound healing. However, its bactericidal efficacy against Gram-negative bacteria is limited under the hypoxic conditions typically found in diabetic wounds. Herein, we report a strategy to develop an efficient chlorophyll-based photosensitizer operating via an oxygen-independent Type I mechanism by combining ZnChl with inorganic salts (NaI, KBr, or KI). This approach significantly improved antibacterial performance, particularly with NaI or KI. Upon 630 nm light irradiation, low concentrations of KI (5 mM) markedly enhanced the bactericidal effect of ZnChl (50 μM), reducing the survival of three Gram-negative bacterial strains by 3 logs (99.9%). Interestingly, we further discovered that KI acts as a "reactive oxygen species (ROS) converter," shifting the photodynamic mechanism of ZnChl from a mixed Type I/Type II mode to a dominant Type I mechanism, generating highly reactive hydroxyl radicals (OH). Moreover, the ZnChl-KI combination demonstrated significant therapeutic efficacy in treating Pseudomonas aeruginosa-infected diabetic wounds without inducing apparent toxicity in rats. This work provides a foundation for developing efficient and economical Type I photosensitizers for the treatment of bacterial infections in diabetic wounds.

395

项与诺格白介素α-因奇西普相关的新闻（医药）

2026-06-13

·基因碗

2025 年薪酬最高的首席科学官与首席医疗官

生物制药行业顶尖科研及医疗高管的薪酬虽远不及首席执行官，但 2025 年仍有部分人员斩获千万美元级薪酬总包。作为行业薪酬系列报道之一，Endpoints News 梳理数百家上市药企与生物科技公司数据，盘点出 2025 年薪酬最高的首席科学官与首席医疗官。共有十位高管去年薪酬总包突破 1000 万美元。榜单中不乏业内知名人士，其中包括身家数十亿的生物科技巨头黄馨祥，以及强生研发负责人约翰・里德。这十位高管 2025 年的收入，均高于生物制药上市企业首席执行官的平均薪酬水平。礼来首席科学与产品官丹・斯科夫龙斯基（Dan Skovronsky）：薪酬总计 1778.66 万美元丹・斯科夫龙斯基此前创办的 Avid Radiopharmaceuticals 公司被这家总部位于印第安纳波利斯的巨头收购后，他于 2010 年正式加入礼来，此后职业生涯一路高歌猛进。2018 年，他出任首席科学官，成功带领礼来摆脱研发领域的弱势局面，搭建起庞大的研发管线，布局涵盖基因药物、前沿肿瘤疗法，以及企业稳居市场主导地位的减肥降糖系列产品。同年 11 月，他再度晋升，岗位职责新增商业化相关工作。目前，斯科夫龙斯基除主管研发业务外，还负责心血管代谢、免疫及神经领域产品的上市推进与产品战略规划。其 2025 年薪酬构成如下：固定薪资 149 万美元、奖金 325 万美元、股权奖励 1200 万美元。公司董事会评价称，在他的推动下，礼来的临床开发效率跻身行业前列。 Palisade Bio 总裁兼首席医疗官米切尔・琼斯（Mitchell Jones）：薪酬总计 1554.66 万美元 Palisade Bio 是一家总部位于丹佛的小型生物科技企业，仅有 14 名员工，企业估值 3.55 亿美元。公司计划在 2026 年第三季度，启动核心候选药物 PALI-2108 治疗溃疡性结肠炎的 II 期临床试验。该药物属于磷酸二酯酶 4 抑制剂。保障项目按计划推进的重任由公司首席医疗官米切尔・琼斯负责，其 2025 年薪酬总额超 1500 万美元。薪酬几乎全部来自价值 1480 万美元的股权奖励。琼斯曾任职于多家小型生物科技公司，包括 Chemomab Therapeutics 与 Finch Therapeutics。 Scholar Rock 研发总裁阿克沙伊・瓦伊什纳夫（Akshay Vaishnaw）：薪酬总计 1489.14 万美元 Scholar Rock 于 2025 年 4 月完成高管团队改组，阿克沙伊・瓦伊什纳夫正式入职。他曾长期任职于 Alnylam，入职前为 Atlas Venture 的投资合伙人。瓦伊什纳夫的薪酬由多部分构成：基本工资 52.31 万美元、绩效奖金 27.83 万美元、股权价值超 1200 万美元，此外还拿到 200 万美元签约奖金。对于尚未实现产品商业化的生物科技公司而言，这笔签约奖金格外丰厚。这家估值 60 亿美元的企业，今年将迎来脊髓性肌萎缩症（SMA）药物的上市审批结果，瓦伊什纳夫将主导公司后续整体发展规划。 Gilead Sciences 首席医疗官迪特马尔・贝格尔（Dietmar Berger）：薪酬总计 1392.29 万美元 2025 年初， Gilead 从赛诺菲高薪挖来迪特马尔・贝格尔，聘任其担任新任首席医疗官。贝格尔主修血液学与肿瘤学，先后任职于 Genentech、拜耳、安进等企业，为招揽这位资深高管，吉利德付出了高昂成本。 Gilead 在股东委托书中表示，公司向贝格尔发放 300 万美元签约奖金以及 450 万美元限制性股票，一方面用于弥补他在原公司损失的薪酬权益，另一方面也以此激励其加盟。此外，贝格尔还获得 30.76 万美元的安家补助。 ImmunityBio 执行董事长兼全球首席科学与医疗官黄馨祥（Patrick Soon-Shiong）：薪酬总计 1223.93 万美元黄馨祥是一位极具营销天赋的生物科技企业家，其身家估值达 166 亿美元。他持有 ImmunityBio 逾 7.45 亿股股份，作为这家 2014 年由他创立的企业，其持股占比接近公司总股本的三分之二。去年，他以公司首席科研与医疗负责人的身份，斩获高额薪酬，其中绝大部分为股权奖励，仅股票期权价值就达 835 万美元。受黄馨祥在社交媒体及播客节目中大力宣传旗下肿瘤疗法 Anktiva 影响，ImmunityBio 股价在 2026 年累计暴涨超 275%。但也正因相关宣传，美国 FDA 于今年向该公司发出警告函。监管部门指出，黄馨祥在《肖恩・斯派瑟访谈节目》中的言论，对 Anktiva 的疗效作出了误导性表述。强生创新药物研发执行副总裁约翰・里德（John Reed）：薪酬总计 1221.41 万美元约翰・里德现已履职满四年，他为公司定下宏大目标，计划在本十年末前推出 20 款新药。里德是免疫学专业出身，于 2023 年 4 月加入强生，数月后便为这家制药巨头制定了上述长期发展规划。加盟强生前，他曾先后担任赛诺菲、罗氏的研发负责人。 Exelixis 研发执行副总裁达纳・阿夫塔布（Dana Aftab）：薪酬总计 1054.72 万美元达纳・阿夫塔布已在 Exelixis 任职逾 25 年。去年 8 月，他获得职务晋升与薪酬上调，全面掌管公司研发业务。阿夫塔布于 1998 年加入这家加州生物科技企业，此前担任首席科学官。履新后，他统筹负责药物发现、基础研究、产品开发及医学事务等工作。 2025 年，阿夫塔布的薪酬构成为：基本工资 65.91 万美元、奖金 39.73 万美元，另获价值 948 万美元的股权奖励。百时美施贵宝前首席医疗官萨米特・希拉瓦特（Samit Hirawat）：薪酬总计 1033.42 万美元多款重磅药物即将迎来仿制药竞争，包括抗凝药艾乐妥与肿瘤药物 Opdivo，这家药企正面临生物制药行业最为严峻的专利断崖冲击，相关药品的专利保护都将在本十年内到期。在此背景下，任职六年的萨米特・希拉瓦特于 2025 年 11 月卸任首席医疗官一职。离职相关款项大幅推高了其 2025 年总收入，其中包含 223 万美元离职补偿金，以及折合 8.58 万美元的未休年假补贴。百时美施贵宝首席医疗官兼研发负责人克里斯蒂安・马萨切西（Cristian Massacesi）：薪酬总计 1007.30 万美元接替希拉瓦特职位的是克里斯蒂安・马萨切西。他此前任职于阿斯利康并担任首席医疗官，于去年 8 月加盟百时美施贵宝，拿到 225 万美元现金签约奖金。该奖金分两笔发放，入职时兑付半数，剩余一半将在今年其入职满一周年时发放。公司股东委托文件显示，马萨切西 2025 年还获得价值 785 万美元的股权奖励，这笔奖励是为补偿其离职原单位的相关权益、促成其入职而发放。辉瑞首席科学官兼研发总裁克里斯・博肖夫（Chris Boshoff）：薪酬总计 1000.60 万美元克里斯・博肖夫此前担任辉瑞肿瘤研发负责人，2025 年初获晋升，接替在辉瑞任职长达 15 年的米卡埃尔・多尔斯滕（Mikael Dolsten）。辉瑞股东委托文件显示，博肖夫 2025 年主要工作成果包括：全年为公司削减 5 亿美元研发开支；主导完成对减肥领域企业 Metsera 的收购，并从中国生物药企三生制药购入一款 PD-1/VEGF 双特异性抗体。 2025 年博肖夫的薪酬总包同比上涨 27%，其中基本工资较 2024 年增加 20 万美元，奖金增加 27 万美元。

2026-06-12

·生物制品圈

生物医药行业薪酬榜：2025年收入最高的CSO与CMO

生物医药行业的顶级科学家和医生虽然远不如CEO赚得多，但仍有一些人在2025年获得了价值超过千万美元的薪酬方案。作为行业薪酬系列报道的一部分，Endpoints News统计了数百家上市制药和生物科技公司，筛选出2025年薪酬最高的首席科学官（CSO）和首席医学官（CMO）。统计显示，共有10位CSO或CMO在2025年获得了价值超过1000万美元的薪酬包。榜单中的许多名字对行业人士来说并不陌生，从身家数十亿美元的生物科技企业家Patrick Soon-Shiong，到强生研发负责人John Reed均位列其中。而他们在2025年的收入，都超过了一家上市生物医药公司CEO的平均薪酬水平。1、礼来首席科学与产品官 Dan Skovronsky：1778.66万美元自2010年加入礼来以来，Dan Skovronsky的职业生涯一路高歌猛进。当时，他创办的Avid Radiopharmaceuticals被礼来收购，他也随之加入这家总部位于印第安纳波利斯的制药巨头。 2018年，Skovronsky被任命为首席科学官（CSO）。他被认为是推动礼来从研发领域相对边缘的位置成长为拥有庞大产品管线企业的重要人物，其布局涵盖基因药物、前沿肿瘤疗法，以及最广为人知的肥胖和减重业务。 2025年11月，他获得进一步晋升，职责新增商业化管理内容。除继续领导研发外，他还负责心血管与代谢疾病、免疫学以及神经科学领域产品的上市和产品战略工作。其2025年薪酬包括：基本工资149万美元奖金325万美元股票奖励1200万美元礼来董事会表示，他帮助公司打造了“业内最快的临床开发体系之一”。 2、Palisade Bio总裁兼首席医学官 Mitchell Jones：1554.66万美元总部位于丹佛的Palisade Bio是一家仅有14名员工的小型生物科技公司，目前市值约3.55亿美元。公司预计将在2026年第三季度启动其核心产品PALI-2108（一种PDE4抑制剂）用于溃疡性结肠炎治疗的Ⅱ期临床试验。确保项目按计划推进的重任落在公司CMO Mitchell Jones肩上。2025年，他获得超过1500万美元的薪酬方案。其中绝大部分来自价值1480万美元的股票奖励。在加入Palisade Bio之前，Jones曾在多家小型生物科技公司任职，包括Chemomab Therapeutics和Finch Therapeutics。3、Scholar Rock研发总裁 Akshay Vaishnaw：1489.14万美元 2025年4月，Scholar Rock对管理层进行了调整，Akshay Vaishnaw成为其中的重要新成员。 Vaishnaw曾长期任职于Alnylam，最近则担任Atlas Venture的风险投资合伙人。其2025年薪酬包括：基本工资52.31万美元绩效奖金27.83万美元签约奖金200万美元超过1200万美元的股权奖励对于一家尚未实现商业化的生物科技公司而言，如此高额的签约奖金尤为引人关注。未来，Vaishnaw将在推动这家市值约60亿美元的生物科技公司发展中发挥关键作用，其中包括其脊髓性肌萎缩症（SMA）药物预计于今年晚些时候迎来的审批决定。4、吉利德科学首席医学官 Dietmar Berger：1392.29万美元 2025年初，吉利德从赛诺菲挖来了Dietmar Berger，出任公司新任首席医学官。为了招募这位血液学和肿瘤学背景的资深专家，吉利德付出了不小代价。 Berger曾先后在Genentech、拜耳和安进任职。根据公司委托书文件披露：签约奖金300万美元限制性股票奖励450万美元搬迁补贴30.76万美元吉利德表示，这些补偿旨在弥补Berger因离开前雇主而放弃的部分薪酬机会，并激励其加入公司。5、ImmunityBio执行董事长兼全球首席科学与医学官 Patrick Soon-Shiong：1223.93万美元 Patrick Soon-Shiong是一位以营销能力著称的生物科技企业家，个人净资产估计达到166亿美元。他持有ImmunityBio超过7.45亿股股份，占这家由其于2014年创立公司的近三分之二股权。除了作为主要股东获得收益外，他还因担任公司最高科学与医学负责人获得了一份可观的薪酬方案。其大部分收入来自股权激励，其中包括价值835万美元的股票期权。 2026年以来，ImmunityBio股价累计上涨超过275%。这一上涨部分归因于Soon-Shiong在社交媒体及播客节目中积极宣传公司癌症疗法Anktiva。不过，这种宣传也引发争议。美国FDA今年早些时候向公司发出警告信，认为Soon-Shiong在《The Sean Spicer Show》节目中的部分表述，可能让公众对Anktiva疗效形成“误导性印象”。6、强生创新制药研发执行副总裁 John Reed：1221.41万美元进入任职第四年后，John Reed为强生制定了雄心勃勃的发展目标，包括在2030年前推出20款新药。 Reed是一位免疫学家，于2023年4月加入强生。在提出上述长期规划前数月，他正式加入这家制药巨头。此前，他曾在赛诺菲和罗氏担任研发负责人。7、Exelixis研发执行副总裁 Dana Aftab：1054.72万美元 Dana Aftab在Exelixis工作超过25年。 2025年8月，他获得晋升并加薪，开始全面负责公司研发业务。 Aftab于1998年加入Exelixis，最近担任首席科学官职务。新岗位负责药物发现、科学研究、产品开发和医学事务。其2025年薪酬包括：基本工资65.91万美元奖金39.73万美元股票奖励948万美元 8、百时美施贵宝前首席医学官 Samit Hirawat：1033.42万美元百时美施贵宝正面临业内最严峻的专利悬崖之一。包括抗凝药Eliquis和肿瘤药Opdivo在内的重磅产品，预计将在2030年前陆续遭遇仿制药竞争。在此背景下，Samit Hirawat于2025年11月离职，结束了其长达六年的首席医学官任期。其2025年总薪酬因离职而显著提高，其中包括： 223万美元离职补偿金 8.58万美元未休假期补偿 9、百时美施贵宝首席医学官兼开发负责人 Cristian Massacesi：1007.30万美元接替Hirawat的是Cristian Massacesi。 Massacesi此前担任阿斯利康首席医学官，于2025年8月加入百时美施贵宝。其获得225万美元现金签约奖金。其中一半在入职时支付，另一半将在其入职满一年后支付。此外，他还获得785万美元股票奖励。公司委托书文件指出，这部分股权奖励是为了补偿其加入公司过程中放弃的原有激励安排。10、辉瑞首席科学官兼研发总裁 Chris Boshoff：1000.60万美元 Chris Boshoff此前负责辉瑞肿瘤研发业务。 2025年初，他被提升为首席科学官兼研发总裁，接替在辉瑞工作15年的研发老将Mikael Dolsten。根据辉瑞委托书文件披露，Boshoff在2025年的主要业绩包括：为研发部门实现5亿美元成本节约；参与推进对肥胖症企业Metsera的投资；参与引进中国生物制药企业三生制药（3SBio）的PD-1/VEGF双特异性抗体项目。其2025年薪酬同比增长27%。与2024年相比：基本工资增加20万美元；奖金增加27万美元。最终，其年度薪酬达到1000.60万美元。参考资料：https://endpoints.news/biopharma-pay-report-top-paid-csos-cmos-of-2025/ 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

2026-06-05

·BioSpace

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. ( NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA ® (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells, across multiple solid tumor indications. “ASCO provides an important opportunity to share emerging clinical and translational data that continue to deepen our understanding of how ANKTIVA-based immunotherapy may restore immune function and rescue or reinvigorate the response to checkpoint inhibitors,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio. “ANKTIVA is the first FDA-approved immunotherapy designed to stimulate NK cells, CD4+ and CD8+ T cells, and memory T cells, which are the very immune cells that are depleted in patients with lymphopenia and that are critical to mounting an effective anti-tumor response. Growing long-term survival data across bladder, lung and other solid tumors are beginning to put in focus a compelling hypothesis: that restoring immune competence and addressing lymphopenia may be as a fundamental to cancer care as targeting the tumor itself. These findings reinforce our conviction that the future of immunotherapy lies in activating and amplifying the immune system, not suppressing it.” Presentation highlights include: ASCO 2026 Annual Meeting Poster Presentations - Sunday, May 31st (9am-12pm) Poster Title: Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy Poster Board: 455am Abstract: #TPS8671 Presenter: Andreas Saltos (Affiliation: Moffitt) Poster Title: Efficacy outcomes in first line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT‑2.023 randomized phase 3 study of IL‑15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy Poster Board: 378 Abstract: #8588 Presenter: John Wrangle (Affiliation: MUSC) Online Publication Only Abstract Title: A matched adjusted indirect comparison (MAIC) of NAI+BCG & pembrolizumab in patients with BCG unresponsive NMIBC with CIS ± papillary disease – Will be published on at 5:00 PM EDT on May 21, 2026 About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA ® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA® is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA ® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. About ImmunityBio ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield ™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 receptor superagonist, ANKTIVA ® (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. For more information, visit ImmunityBio.com and connect with us on X (Twitter), Facebook , LinkedIn , and Instagram . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development of ANKTIVA® (nogapendekin alfa inbakicept-pmln), the potential benefits of ANKTIVA-based immunotherapy in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC), future regulatory submissions and approvals, commercialization plans and market potential, and the company's strategic vision for restoring immune competence in cancer patients. These forward-looking statements are based on ImmunityBio's current expectations and beliefs and are subject to uncertainties and factors that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to: the risk that clinical trials may not demonstrate adequate safety and efficacy to support regulatory approval or may be delayed or terminated; the risk that regulatory authorities may not approve ANKTIVA for additional indications or may impose restrictions on its use; the risk that the company may not successfully commercialize ANKTIVA or achieve market acceptance; competition from other therapies; manufacturing and supply chain risks; intellectual property risks; and the company's ability to obtain additional funding to support its operations. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2026 as well as its Form 10-Q filed with the SEC on May 7, 2026, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at . ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 858-746-9289 Hemanth.Ramaprakash@ImmunityBio.com Media Sarah Singleton ImmunityBio, Inc. +1 415-290-8045 Sarah.Singleton@ImmunityBio.com

100 项与诺格白介素α-因奇西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12888	-	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性非小细胞肺癌	沙特阿拉伯	ImmunityBio, Inc.	2026-04-21
原位癌	欧盟	ImmunityBio, Inc.	2026-02-16
原位癌	冰岛	ImmunityBio, Inc.	2026-02-16
原位癌	列支敦士登	ImmunityBio, Inc.	2026-02-16
原位癌	挪威	ImmunityBio, Inc.	2026-02-16
非肌层浸润性膀胱尿路上皮癌	沙特阿拉伯	ImmunityBio, Inc.	2026-01-14
淋巴细胞减少	美国	ImmunityBio, Inc.	2025-06-02
非肌层浸润性膀胱肿瘤	美国	Altor BioScience Corp.	2024-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
社区获得性肺炎	临床3期	-	ImmunityBio, Inc.	2026-04-15
急性呼吸窘迫综合征	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒症	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒性休克	临床3期	-	ImmunityBio, Inc.	2026-04-15
肺癌	临床3期	美国	ImmunityBio, Inc.	2022-07-27
晚期非小细胞肺癌	临床3期	美国	ImmunityBio, Inc.	2018-05-18
膀胱癌	临床3期	美国	ImmunityBio, Inc.	2017-06-02
HPV阳性的口咽鳞状细胞癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
HPV16阳性口咽癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
复发性胶质母细胞瘤	临床2期	-	ImmunityBio, Inc.	2026-07-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02782546 (CTgov)	临床2期	急性髓性白血病 \| 难治性急性髓细胞白血病	60	G-CSF+ALT-803+Tacrolimus+mycophenolate mofetil+CIML NK cell infusion (Recipient)	餘遞顧鹽遞觸範餘衊淵 = 顧鹹選顧築廠簾憲醖簾齋窪鑰鹹範壓廠鏇觸構 (構壓蓋鏇齋窪壓積壓範, 遞醖餘簾選範壓鏇繭構 ~ 艱鑰鬱餘築獵鬱遞鹽構) 更多	-	2026-06-01
				Leukapheresis (Donor)	遞醖範網壓醖鏇製範憲(餘鬱鏇齋廠醖壓壓衊製) = 鑰鏇淵艱積夢艱選選鏇膚簾襯鏇憲膚製選淵範 (廠鹹壓齋艱鹽製鹽齋夢, 鬱網窪夢網範餘夢顧齋 ~ 遞襯鑰遞鹹壓蓋淵願壓) 更多
NCT03520686 (QUILT-2.023, ASCO2026)	临床3期	非小细胞肺癌一线 PD-L1 TPS	98	CPI+NAI	築顧積獵簾獵網積鏇醖(窪襯鬱繭築繭艱夢構窪) = 窪網顧簾襯膚淵膚顧鏇鑰廠醖選襯壓構積艱淵 (觸觸醖鏇壓選鑰網範鹽 ) 更多	积极	2026-05-29
				CPI	築顧積獵簾獵網積鏇醖(窪襯鬱繭築繭艱夢構窪) = 壓網觸範齋積範鹹觸壓鑰廠醖選襯壓構積艱淵 (觸觸醖鏇壓選鑰網範鹽 ) 更多
NCT03022825 (QUILT-3.032, ASCO2026)	临床3期	非肌层浸润性膀胱肿瘤	173	nogapendekin alfa inbakicept-pmln + BCG (NAI+BCG)	繭簾鏇蓋衊鑰鹹憲選淵(簾鬱築齋齋鏇範壓膚鑰) = 餘鏇鏇衊膚鹹繭鑰膚製襯壓襯淵選鬱糧襯構築 (顧網襯築蓋壓獵夢鹹積 ) 更多	积极	2026-05-29
				pembrolizumab (PEMBRO)	繭簾鏇蓋衊鑰鹹憲選淵(簾鬱築齋齋鏇範壓膚鑰) = 繭齋鬱醖範範鑰鹽鑰糧襯壓襯淵選鬱糧襯構築 (顧網襯築蓋壓獵夢鹹積 ) 更多
NCT05419011 (TRIAD5-Plus, Pubmed \| Front Immunol)	临床2期	遗传性非息肉病性结直肠癌 Lynch syndrome	158	Tri-Ad5	窪構糧繭鹹淵鏇憲齋獵(衊鑰襯衊醖構淵憲餘範) = 範夢餘鬱範廠築獵獵艱廠積淵醖齋衊餘壓築醖 (糧構膚淵窪衊壓簾範壓 )	积极	2026-05-19
				Tri-Ad5 + NAI	窪構糧繭鹹淵鏇憲齋獵(衊鑰襯衊醖構淵憲餘範) = 憲鹽積鏇鏇窪窪顧壓願廠積淵醖齋衊餘壓築醖 (糧構膚淵窪衊壓簾範壓 )
NCT06745908 (ResQ201A, ESMO_ELCC2026)	临床3期	-	462	NAI+tislelizumab+docetaxel	齋構觸夢鏇艱襯窪願艱(鹹齋壓築鏇選鏇簾鹹蓋) = 齋顧選鏇顧壓壓範築鬱顧範憲糧繭蓋憲繭鑰膚 (選構築淵願簾鬱簾廠築 ) 更多	积极	2026-03-25
				docetaxel	齋構觸夢鏇艱襯窪願艱(鹹齋壓築鏇選鏇簾鹹蓋) = 製艱願蓋餘簾觸網醖廠顧範憲糧繭蓋憲繭鑰膚 (選構築淵願簾鬱簾廠築 ) 更多
NCT02523469 (CTgov)	临床1/2期	转移性非小细胞肺癌	67	ALT-803+Nivolumab (Cohort 1: ALT-803 6 µg/kg + Nivolumab 3 mg/kg)	廠窪顧獵醖淵淵觸壓鏇 = 壓艱襯築鏇壓鹹鏇構獵鑰淵壓憲網構艱鏇廠糧 (鏇憲鏇襯衊蓋製廠築糧, 範築築醖願齋壓糧蓋窪 ~ 選觸糧顧鑰鏇窪衊鹹獵) 更多	-	2026-02-17
				ALT-803+Nivolumab (Cohort 2: ALT-803 10 µg/kg + Nivolumab 3 mg/kg)	廠窪顧獵醖淵淵觸壓鏇 = 鹽築夢鬱鹹範醖網願餘鑰淵壓憲網構艱鏇廠糧 (鏇憲鏇襯衊蓋製廠築糧, 艱夢鑰鬱簾窪齋艱膚鏇 ~ 鹽鏇淵膚繭窪壓襯鹹鬱) 更多
NCT04491955 (Pubmed \| Oncologist)	临床1/2期	转移性结直肠癌 pMMR	32	CV-301 + N-803 + bintrafusp alfa + PDS01ADC	餘壓蓋獵鬱艱憲壓獵獵(繭觸獵廠鬱簾繭襯餘壓) = 壓鬱窪鏇夢醖淵觸鹽網構襯構鹽蓋願積願願遞 (鹹繭鏇廠夢獵鏇網願鹽 ) 更多	不佳	2026-02-05
NCT03520686 (QUILT-2.023, Company_Website) 人工标引	临床3期	转移性非小细胞肺癌 \| 晚期非小细胞肺癌一线	-	ANKTIVA + CPI	獵艱糧簾鏇壓夢憲憲憲(願鹽鏇憲簾衊顧糧壓襯): P-Value = 0.0065	积极	2026-01-13
				CPI
NCT03228667 (QUILT-3.055, Company_Website) 人工标引	临床2期	非小细胞肺癌二线	-	ANKTIVA + CPI (NSCLC)	憲憲觸遞廠鑰簾膚衊鏇(淵鹹衊糧鹹選夢遞鹹艱) = 鹹製夢鹹壓鑰鬱壓夢憲窪觸觸膚餘網築鑰願鏇 (襯淵憲繭顧遞製醖鹽鏇 )	积极	2026-01-13
				ANKTIVA + CPI (NSCLC + Responders)	壓壓壓壓齋憲構壓繭觸(獵觸窪繭鹽範壓觸願鬱) = 醖觸廠願繭鬱壓鹹積鏇襯鬱製鹽壓鹹壓夢淵鑰 (憲鹽淵夢鹽鬱構顧窪構 )
NCT03022825 (QUILT-3.032, Pubmed \| J Urol)	临床2期	-	54	NAI plus BCG (BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer)	鹽鬱淵築餘鬱鬱構衊壓(選淵窪餘廠遞壓觸淵糧) = 遞齋襯築獵遞餘憲鑰壓糧繭鹽淵淵範鑰蓋觸廠 (繭鏇構憲糧夢衊餘夢鹽, 46.6 ~ 68.2) 更多	积极	2026-01-01